Evaluation of Intra-articular Injection of Autologous Protein Solution ("APS(TM)") for the Treatment of Osteoarthritis (OA)
A Prospective Single-Center Clinical Study of a Single Intra-Articular Injection of Autologous Protein Solution ("APS(TM)") in Patients With Osteoarthritis (OA) of the Knee
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Geldrop, Netherlands
- St. Anna Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Eligibility Criteria:
- Male or female ≥40 years.
- Willingness and ability to comply with the study procedures and visit schedules and ability to follow verbal and written instructions.
- A standing radiograph of the knee showing a Kellgren grade of 2 or 3
- Frequency of knee pain on most days over the last month.
- Diagnosis of unilateral knee OA
- Body mass index (BMI) ≤40 kg/m2.
- Failed conservative OA therapy.
- Signed an independent ethics committee (IEC)-approved informed consent form (ICF).
- Willingness to abstain from the use of topical pain therapies, intra-articular corticosteroids, and viscosupplementation during the study.
- Willingness to abstain from systemic pain medications except rescue medication.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Autologous Protein Solution "APS(TM)"
Patients who have been treated with a single, intra-articular injection.
|
A therapy prepared at the point-of-care from a small sample of the patient's own blood containing high concentrations of anti-inflammatory and anabolic proteins
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Adverse Events
Time Frame: Up to 6 months post-injection
|
Safety and tolerability will be assessed from AEs and injection-site reactions, physical examinations, knee examinations, vital signs, ECGs, and clinical laboratory tests (hematology, coagulation, blood chemistry, and urinalysis) evaluated at baseline (pre-injection) and post-injection up to 6 months.
|
Up to 6 months post-injection
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Patients Using Rescue Medication
Time Frame: Up to 6 months post-injection
|
Explore the potential for an analgesic effect of a single dose of APS in patients with OA of the knee.
|
Up to 6 months post-injection
|
|
Pain Score
Time Frame: Baseline, Week 1, Week 2, and at Months 1, 3, and 6.
|
The Western Ontario and McMaster Universities osteoarthritis index questionnaire using the Likert scale (WOMAC LK), Version 3.1 questionnaire has 24 items that the patient addresses about the knee: 5 items on the pain subscale, 2 on the stiffness subscale, and 17 on the physical function subscale.
Each item was to be answered on a 5-point Likert scale, with grading from 0 (none or never) to 4 (extreme or always).
The scores are summed for items in each subscale, with possible ranges as follows: pain=0-20, stiffness=0-8, physical function=0-68.
A higher score indicates worse pain, stiffness, or functional limitation.
|
Baseline, Week 1, Week 2, and at Months 1, 3, and 6.
|
|
Stiffness Score
Time Frame: Baseline, Week 1, Week 2, and at Months 1, 3, and 6.
|
Changed Outcome Measure Description to: The Western Ontario and McMaster Universities osteoarthritis index questionnaire using the Likert scale (WOMAC LK), Version 3.1 questionnaire has 24 items that the patient addresses about the knee: 5 items on the pain subscale, 2 on the stiffness subscale, and 17 on the physical function subscale.
Each item was to be answered on a 5-point Likert scale, with grading from 0 (none or never) to 4 (extreme or always).
The scores are summed for items in each subscale, with possible ranges as follows: pain=0-20, stiffness=0-8, physical function=0-68.
A higher score indicates worse pain, stiffness, or functional limitation.
|
Baseline, Week 1, Week 2, and at Months 1, 3, and 6.
|
|
Physical Function Score
Time Frame: Baseline, Week 1, Week 2, and at Months 1, 3, and 6.
|
Changed Outcome Measure Description to: The Western Ontario and McMaster Universities osteoarthritis index questionnaire using the Likert scale (WOMAC LK), Version 3.1 questionnaire has 24 items that the patient addresses about the knee: 5 items on the pain subscale, 2 on the stiffness subscale, and 17 on the physical function subscale.
Each item was to be answered on a 5-point Likert scale, with grading from 0 (none or never) to 4 (extreme or always).
The scores are summed for items in each subscale, with possible ranges as follows: pain=0-20, stiffness=0-8, physical function=0-68.
A higher score indicates worse pain, stiffness, or functional limitation.
|
Baseline, Week 1, Week 2, and at Months 1, 3, and 6.
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: R.A.M. van Drumpt, M.D., St. Anna Hospital, Geldrop, NL
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- APSS-11-00
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.